Most Popular
-
1
1 in 3 Koreans live alone, family types becoming diverse
-
2
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
3
K-pop singer lost consciousness after being hit by foul ball, cancels show
-
4
K-pop group's manager dismissed for setting up spycam in theater dressing room
-
5
Contentious grain bill put directly to plenary meeting for vote
-
6
Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
-
7
Why is Apple Pay struggling to get purchase in Korea?
-
8
Yoon's office denies considering liberal figures for key posts
-
9
Trilateral talks acknowledge ‘serious’ slumps of won, yen
-
10
[Today’s K-pop] BTS pop-up event to come to Seoul
![[Today’s K-pop] BTS pop-up event to come to Seoul](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050734_0.jpg&u=)
![[Today’s K-pop] BTS pop-up event to come to Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050734_0.jpg&u=)
Samsung Bioepis’ breast cancer treatment biosimilar launches in US
By Lim Jeong-yeoPublished : April 16, 2020 - 17:12
Samsung Bioepis’ breast cancer treatment Ontruzant (trastuzumab) was launched in the US via local partner Merck, Thursday.
Ontruzant references Roche’s blockbuster original Herceptin, which recorded annual global revenue of approximately 7.2 trillion won ($5.8 billion) in 2019.
The US accounts for about 45 percent of Herceptin sales.
Samsung Bioepis strategizes to sell Ontruzant at a 15 percent more affordable rate than Herceptin, as well as to offer doses of 150 milligrams and 420 milligrams to expand prescription options.
This is the second biosimilar that Samsung Bioepis has launched in the US, the biggest pharmaceuticals market in the world, following rheumatoid arthritis treatment Renflexis in 2017. Renflexis references Janssen’s Remicade (infliximab).
Merck is also responsible for Renflexis’ US sales.
Samsung Bioepis also has US commercialization approvals for its Enbrel (etanercept) biosimilar Eticovo and Humira (adalimumab) biosimilar Hadlima. Both drugs treat rheumatoid arthritis. They have yet to be launched for the US market.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
Ontruzant references Roche’s blockbuster original Herceptin, which recorded annual global revenue of approximately 7.2 trillion won ($5.8 billion) in 2019.
The US accounts for about 45 percent of Herceptin sales.
Samsung Bioepis strategizes to sell Ontruzant at a 15 percent more affordable rate than Herceptin, as well as to offer doses of 150 milligrams and 420 milligrams to expand prescription options.
This is the second biosimilar that Samsung Bioepis has launched in the US, the biggest pharmaceuticals market in the world, following rheumatoid arthritis treatment Renflexis in 2017. Renflexis references Janssen’s Remicade (infliximab).
Merck is also responsible for Renflexis’ US sales.
Samsung Bioepis also has US commercialization approvals for its Enbrel (etanercept) biosimilar Eticovo and Humira (adalimumab) biosimilar Hadlima. Both drugs treat rheumatoid arthritis. They have yet to be launched for the US market.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
